TSE:4502Pharmaceuticals
How FDA Priority Review for Rusfertide and Renewed Actos Claims Will Impact Takeda Pharmaceutical (TSE:4502) Investors
In early March 2026, Takeda and Protagonist Therapeutics announced that the U.S. FDA accepted and granted Priority Review to their New Drug Application for rusfertide, a first-in-class hepcidin mimetic for adults with polycythemia vera, while a U.S. court certified a national third-party payor class in long-running Actos litigation over alleged concealment of bladder cancer risks.
Together, the potential for rusfertide to reach patients sooner under expedited FDA review and the renewed legal...